10 Fastest Growing NASDAQ Stocks to Buy

Page 9 of 9

1. Viridian Therapeutics, Inc. (NASDAQ:VRDN)

On February 27, 2026, RBC Capital lowered its price target on Viridian Therapeutics, Inc. (NASDAQ:VRDN) to $42 from $45 and maintained an Outperform rating. The analyst noted the company reported Q4 EPS and disclosed that veli’ PDUFA is scheduled for June 30, with preparations underway for a potential commercial launch in thyroid eye disease in mid-2026 if approved. RBC said it continues to favor the company’s positioning in 2026 as it could transition to the commercial stage and move closer to profitability.

On February 26, 2026, Jefferies raised its price target to $45 from $44 and kept a Buy rating. The firm said all key events remain on track and that investor focus is on the Phase 3 topline readout of subcutaneous elegrobart in REVEAL-1 in Q1, REVEAL-2 in Q2, and the PDUFA decision due June 30 for intravenous veligrotug under priority review.

That same day, Viridian Therapeutics reported Q4 EPS of ($1.08), compared to the ($1.00) consensus estimate. Q4 revenue was $132,000 versus the consensus of $15.75M. President and Chief Executive Officer Steve Mahoney said the company enters 2026 with continued execution momentum, highlighting the veligrotug BLA filing under Priority Review and a June 30, 2026, PDUFA target date. He added that the MAA submission to the EMA supports the global opportunity for veligrotug and that REVEAL-1 topline data for elegrobart is expected next month, with the goal of establishing veligrotug and elegrobart as foundational therapies for TED while advancing the broader pipeline.

Viridian Therapeutics, Inc. (NASDAQ:VRDN) discovers, develops, and commercializes treatments for serious and rare diseases, including IGF-1R therapies for thyroid eye disease.

While we acknowledge the potential of VRDN to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than VRDN and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 12 Best Tech Stocks that Beat Earnings Estimates and 40 Most Popular Stocks Among Hedge Funds Heading Into 2026

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.

Page 9 of 9